Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab in primary membranous nephropathy
NCT06642909Phase 2Active, not recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zuberitamab in primary membranous nephropathy (PMN), sponsored by BioRay Pharmaceutical. Started Nov 2024; status: active, not recruiting.
02
Drugs
zuberitamab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06642909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642909.